Several preclinical and clinical studies have shown that Bindarit, via suppressing the production of CCL2 and reducing the recruitment of monocytes and macrophages, is effective in treating inflammatory-based disorders, such as diabetes-associated periodontitis (animal model study) (187), lupus nephritis (human study) (188), Alzheimer’s disease (in vitro study) (189), and experimental autoimmune encephalomyelitis (EAE) (animal model study) (190). This evidence concerns the gene CCL2 and lupus nephritis.